<ul><li>Wockhardt, a pharmaceutical company, will not face significant impact of the global turmoil over US tariffs due to its strong business model.</li><li>Wockhardt's exposure to the US market is just 5% and it is planning to exit the generic business in the country soon.</li><li>Other pharma companies with substantial exposure to the US may need to adjust their strategy and look at other markets like Europe to compensate for the potential impact of tariffs.</li><li>The tariffs will increase the cost burden for US consumers, as a significant portion of generic prescriptions in the country are met by Indian products.</li></ul>

Wockhardt Not To Face Significant Impact Of US Tariffs, Says Chairman Khorakiwala

Discover more